Literature DB >> 221923

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.

A B DeLeo, G Jay, E Appella, G C Dubois, L W Law, L J Old.   

Abstract

Antisera prepared against BALB/c Meth A sarcoma in syngeneic or compatible F1 mice recognize a protein with an apparent molecular weight of 53,000 in extracts of [35S]methionine-labeled transformed BALB/c cells. This component, designated p53, was not detected in normal adult mouse fibroblasts, lymphoid cells, or hematopoietic cells or in mouse embryo cells or 3T3 cells. An extensive variety of antisera, including alloantisera and heterologous antisera directed against structural antigens of murine leukemia viruses, was tested for reactivity with p53; other than Meth A antisera, only comparably prepared antisera against another BALB/c sarcoma, CMS4, had anti-p53 activity. All transformed mouse cells tested were found to express p53; these tests included chemically induced sarcomas, leukemias, spontaneously transformed fibroblasts, and cells transformed by simian virus 40 and murine sarcoma virus. The presence of p53 in tumors of no known viral etiology indicates coding by resident cellular genes; this does not exclude endogenous viruses as the source of coding sequences or the possibility that transforming viruses code directly for p53.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 221923      PMCID: PMC383613          DOI: 10.1073/pnas.76.5.2420

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  STUDIES ON INDUCED RESISTANCE AGAINST ISOTRANSPLANTS OF VIRUS-INDUCED LEUKEMIA.

Authors:  J P GLYNN; A R BLANCO; A GOLDIN
Journal:  Cancer Res       Date:  1964-04       Impact factor: 12.701

2.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

Authors:  G KLEIN; H O SJOGREN; E KLEIN; K E HELLSTROM
Journal:  Cancer Res       Date:  1960-12       Impact factor: 12.701

3.  Immunity to methylcholanthrene-induced sarcomas.

Authors:  R T PREHN; J M MAIN
Journal:  J Natl Cancer Inst       Date:  1957-06       Impact factor: 13.506

4.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.

Authors:  E J FOLEY
Journal:  Cancer Res       Date:  1953-12       Impact factor: 12.701

5.  Translation of polyoma virus T antigens in vitro.

Authors:  T Hunter; M A Hutchinson; W Eckhart
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

6.  Expression of simian virus 40 early genes in transformed rat cells is correlated with maintenance of the transformed phenotype.

Authors:  P Gaudray; M Rassoulzadegan; F Cuzin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

7.  Tumor antigen(s) in cell productively infected by wild-type polyoma virus and mutant NG-18.

Authors:  B S Schaffhausen; J E Silver; T L Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

8.  Comparison of the genomic organization of Kirsten and Harvey sarcoma viruses.

Authors:  T Y Shih; D R Williams; M O Weeks; J M Maryak; W C Vass; E M Scolnick
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

9.  Biological and biochemical properties of Nonidet P40-solubilized and partially purified tumor-specific antigens of the transplantation type from plasma membranes of a methylcholanthrene-induced sarcoma.

Authors:  T Natori; L W Law; E Appella
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

10.  G(AKSL2): a new cell surface antigen of the mouse related to the dualtropic mink cell focus-inducing class of murine leukemia virus detected by naturally occurring antibody.

Authors:  E Stockert; A B DeLeo; P V O'Donnell; Y Obata; L J Old
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

View more
  205 in total

1.  Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.

Authors:  E M Tan
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

3.  The history of p53. A perfect example of the drawbacks of scientific paradigms.

Authors:  Thierry Soussi
Journal:  EMBO Rep       Date:  2010-10-08       Impact factor: 8.807

4.  Characterization of the human p53 gene promoter.

Authors:  S P Tuck; L Crawford
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

5.  Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment.

Authors:  O Halevy; A Hall; M Oren
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

Review 6.  A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Authors:  Olivera J Finn
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

7.  Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.

Authors:  E Harlow; N M Williamson; R Ralston; D M Helfman; T E Adams
Journal:  Mol Cell Biol       Date:  1985-07       Impact factor: 4.272

8.  AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization.

Authors:  T E Carey; K O Lloyd; T Takahashi; L R Travassos; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

9.  High-frequency cotransfer of the transformed phenotype and a tumor-specific transplantation antigen by DNA from the 3-methylcholanthrene-induced Meth A sarcoma of BALB/c mice.

Authors:  N Hopkins; P Besmer; A B DeLeo; L W Law
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

Review 10.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.